medigraphic.com
ISSN 1561-2945 (Print)

2020, Number 4

<< Back Next >>

Revista Cubana de Cirugía 2020; 59 (4)

The value of mediastinal lymphadenectomy in lung cancer surgery

García RME, Rodríguez MOS, García BMJ, Benavidez MA, Koelig PR

Language: Spanish
References: 35
Page: 1-15
PDF size: 559.59 Kb.


ABSTRACT

Introduction: Evaluation of the mediastinum in patients receiving surgical treatment for lung cancer has its origins in the need to define the anatomical extension of each node station, which is essential for the pathological categorization of lymph nodes.
Objective: To evaluate the usefulness of mediastinal lymphadenectomy in the surgical treatment of lung cancer.
Methods: A prospective and analytical study was carried out in the period from January 2015 to August 31, 2018. The universe consisted of 96 patients with some type of mediastinal lymphadenectomy in the surgical treatment of lung cancer within the indicated period. Statistical, theoretical and empirical methods were used.
Results: The average age was 58.69 ± 9.343. The male sex was the most affected. Adenocarcinoma was the histological type that predominated. The most manifested clinical and pathological stage was III A. Right upper lobectomy was the most performed intervention. A total of 76 systematic lymph node dissections were performed, followed by 18 lymph node samples and two biopsies. The lymphadenectomies performed caused stage changes in 46 patients. The analysis of positive and negative predictive value, as well as sensitivity and specificity, were high. There were few complications.
Conclusions: Mediastinal lymphadenectomy as part of the surgical treatment in lung cancer constitutes a fundamental procedure for the pathological staging of TNM, as it shows high diagnostic accuracy.


REFERENCES

  1. Hunt KK, Mittendorf EA. Enfermedades de la mama. En: Sabiston D, Townsend C. Tratado de cirugía. 20th ed. Barcelona: Elsevier; 2018. p. 820-64.

  2. Deslauries J. Mediastinal lymph nodes: Ignore? Sample? Dissect? The role of mediastinal node dissection in the surgical management of primary lung cancer. Gen Thorac Cardiovasc Surg. 2012;60:724-34.

  3. Riquet M, Pricopi C, Arame A, Le Pimpec Barthes F. From anatomy to lung cancer: questioning lobe-specific mediastinal lymphadenectomy reliability. J Thorac Dis. 2016;8(9):2387-90.

  4. Deng Y, Wang J, Mu J, Wang Z, Wang G. Complete Uniportal Thoracoscopic Anatomic Lung Resection With Systematic Mediastinal Lymphadenectomy for Non-Small Cell Lung Cancer: Personal Experience of 326 Cases. Surg Laparosc Endosc Percutan Tech. 2020;30(2):173-9.

  5. Wang W, Chen D, Xi K, Chen Y, Zhang X, Wen Y, et al. Impact of Different Types of Lymphadenectomy Combined With Different Extents of Tumor Resection on Survival Outcomes of Stage I Non-small-cell Lung Cancer: A Large-Cohort Real-World Study. Front Oncol. 2019;9:642.

  6. Cahan WG, Watson WL, Pool JL. Radical pneumonectomy. J Thorac Surg. 1951;22:449-473

  7. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg. 1978;76:833-9.

  8. Mokhles S, Macbeth F, Treasure T, Younes RN, Rintoul RC, Fiorentino F, et al. Systematic lymphadenectomy versus sampling of ipsilateral mediastinal lymph-nodes during lobectomy for non-small-cell lung cancer: a systematic review of randomized trials and a meta-analysis. Eur J Cardiothorac Surg. 2017;51(6):1149-56.

  9. Le Pimpec-Barthes F, Riquet M. Quality of Lymphadenectomy in Lung Cancer. Ann Thorac Surg. 2015;100(2):768.

  10. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.

  11. Chida M. Why non-grasping-lymphadenectomy technique is necessary for lung cancer resection? J Thorac Dis. 2019;11(1):57-8.

  12. Pita Fernández S, Pértegas Díaz S. Pruebas diagnósticas: Sensibilidad y especificidad. Cad Aten Primaria. 2003;10:120-24.

  13. Colectivo de autores. Anuario Estadístico de la Salud Cuba 2019. Dirección de Registros Médicos y Estadísticas de Salud. MINSAP. 2019 [acceso 20/03/2020]:50-70. Disponible en: http://www.sld.cu/anuncio/2020/05/09/publicado-el-anuario-estadistico-de-salud-2019

  14. Zheng E, Yang M, Li R, Ni J, Xu X, Zhao G, et al. Prognostic impact of lymphadenectomy on outcomes of sublobar resection for non-small cell lung cancer </=1 or >1 to 2 cm. J Thorac Dis. 2020;12(5):2049-60.

  15. Stiles BM, Mao J, Harrison S, Lee B, Port JL, Sedrakyan A, et al. Extent of lymphadenectomy is associated with oncological efficacy of sublobar resection for lung cancer </=2 cm. J Thorac Cardiovasc Surg. 2019;157(6):2454-65.

  16. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines): non-small cell lung cancer, version 1. 2020 [acceso 20/03/2020]. Disponible en: https://www.nccn.org/patients/guidelines/cancers.aspx#nsclc

  17. Wo Y, Zhao Y, Qiu T, Li S, Wang Y, Lu T, et al. Impact of visceral pleural invasion on the association of extent of lymphadenectomy and survival in stage I non-small cell lung cancer. Cancer Med. 2019;8(2):669-78.

  18. Meng D, Zhou Z, Wang Y, Wang L, Lv W, Hu J, et al. Lymphadenectomy for clinical early-stage non-small-cell lung cancer: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2016;50(4):597-604.

  19. Meng D, Zhou Z, Wang Y, Wang L, Lv W, Hu J, et al. Lymphadenectomy for clinical early-stage non-small-cell lung cancer: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2016;50(4):597-604.

  20. Yendamuri S, Dhillon SS, Groman A, Dy G, Dexter E, Picone A, et al. Effect of the number of lymph nodes examined on the survival of patients with stage I non-small cell lung cancer who undergo sublobar resection. J Thorac Cardiovasc Surg. 2018;156(1):394-402.

  21. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39-51.

  22. Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015;10(7):990-1003.

  23. De Leyn P, Cooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;30:787-92.

  24. Little AG, Rusch VW, Bonner JA, Gaspar LE, Green MR, Webb WR, et al. Patterns of Surgical Care of Lung Cancer Patients. Ann Thorac Surg. 2005;80:2051-6.

  25. Watanabe S, Asamura H. Lymph node dissection for lung cancer: significance, strategy, and technique. J Thorac Oncol. 2009;4:652-7.

  26. Cerfolio RJ, Bryant AS. Survival of patients with unsuspected N2 (Stage IIIA) non small-cell lung cancer. Ann Thorac Surg. 2008;86:362-7.

  27. Allen MS, Darling GE, Pechet TT, Mitchell JD, Herndon JE, Landreneau RJ, et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg. 2006;81(3):1013-9.

  28. Pu Q, Liu C, Liu L. Good Method and Standardization Is Much Needed in VATS Mediastinal Lymphadenectomy for Lung Cancer. Ann Thorac Surg. 2016;102(2):673.

  29. Wang X, Yan S, Phan K, Yan TD, Zhang L, Yang Y, et al. Mediastinal lymphadenectomy fulfilling NCCN criteria may improve the outcome of clinical N0-1 and pathological N2 non-small cell lung cancer. J Thorac Dis. 2016;8(3):342-9.

  30. Tanoue LT. Lung Cancer Staging. Clin Chest Med. 2020;41(2):161-74.

  31. López Encuentra A, Gómez de la Cámara A, Varela de Ugarte A, Mañes N, Llobregat N. El fenómeno "Will-Rogers". Migración de estadios en carcinoma broncogénico, tras aplicar criterios de certeza clasificatoria. Arch Bronconeumol. 2002;38(4):166.

  32. Hegde P, Molina JC, Thivierge-Southidara M, Jain RV, Gowda A, Ferraro P, et al. Combined Endosonographic Mediastinal Lymph Node Staging in Positron Emission Tomography and Computed Tomography Node-Negative Non-Small-Cell Lung Cancer in High-Risk Patients. Semin Thorac Cardiovasc Surg. 2020;32(1):162-8.

  33. Amini A, Lou F, Correa AM, Baldassarre R, Rimner A, Huang J, et al. Predictors for Locoregional Recurrence for Clinical Stage III-N2 Non-small Cell Lung Cancer with Nodal Down staging After Induction Chemotherapy and Surgery. Ann SurgOncol. 2013;20:1934-40.

  34. Wang S, Lin D, Yang X, Zhan C, Zhao S, Luo R, et al. Clinical significance of PET/CT uptake for peripheral clinical N0 non-small cell lung cancer. Cancer Med. 2020;9(7):2445-53.

  35. Majem M, Hernandez-Hernandez J, Hernando-Trancho F, Rodriguez de Dios N, Sotoca A, Trujillo-Reyes JC, et al. Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer. Clin Transl Oncol. 2020;22(1):21-36.




2020     |     www.medigraphic.com